Skip to main content

Table 1 Sample characteristics and disease presenting features

From: The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting

  All (n = 163) HIV - (n = 116) HIV + (n = 47) P-value NHL (n = 122) HL (n = 41) P-value
Sex
 Male 94 58% 72 62% 22 47% 0.07 70 57% 24 59%  
 Female 69 42% 44 38% 25 53%   52 43% 17 41% 0.90
Age
 Median (IQR) 48 (33–59) 54 (37–62) 38 (30–47) < 0.01 51 (38–61) 35 (28–45) < 0.01
   < 18 3 2% 3 3% 0 0%   2 2% 1 2%  
  18–39 57 35% 30 26% 27 57%   34 28% 23 56%  
  40–59 66 40% 46 40% 20 43%   52 43% 14 34%  
  60–79 35 21% 35 30% 0 0%   32 26% 3 7%  
  80 or older 2 1% 2 2% 0 0%   2 2% 0 0%  
Race
 Mixed ancestry 81 50% 77 66% 4 9% < 0.01 62 51% 19 46%  
 Black 59 36% 18 16% 41 87%   40 33% 19 46%  
 White 23 14% 21 18% 2 4%   20 16% 3 7% 0.18
Performance score
 ECOG 0 19 12% 14 12% 5 11% 0.97 11 9% 8 20%  
 ECOG 1 74 45% 54 47% 20 43%   53 43% 21 51%  
 ECOG 2 27 17% 19 16% 8 17%   21 17% 6 15%  
 ECOG 3 32 20% 22 19% 10 21%   27 22% 5 12%  
 ECOG 4 11 7% 7 6% 4 9%   10 8% 1 2% 0.17
Stage of disease at presentation
 Stage 1 23 14% 18 16% 5 11% 0.23 22 18% 1 2% 0.04
 Stage 2 35 21% 27 23% 8 17%   28 23% 7 17%  
 Stage 3 19 12% 10 9% 9 19%   13 11% 6 15%  
 Stage 4 86 53% 61 53% 25 53%   59 48% 27 66%  
 Bone marrow involved at diagnosis 41 25% 23 20% 18 38% 0.03 23 19% 18 44% < 0.01
Clinical presentation and investigations
 Peripheral lymphadenopathy 104 64% 73 63% 31 66% 0.72 69 57% 35 85% < 0.01
 B Symptoms 96 59% 66 57% 30 64% 0.42 66 54% 30 73% 0.03
 Diagnosis made on bone marrow 10 6% 5 4% 5 11% 0.66 4 3% 6 15% 0.23
 On TB therapy at diagnosis 16 10% 4 3% 12 26% < 0.01 5 4% 11 27% < 0.01
FNAC
 Performed 63 39% 44 38% 19 40% 0.77 39 32% 24 59% < 0.01
 Not performed 100 61% 72 62% 28 60%   83 68% 17 41%